A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer’s disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporat...

Descripción completa

Detalles Bibliográficos
Autores principales: Brum, Wagner S., Cullen, Nicholas C., Janelidze, Shorena, Ashton, Nicholas J., Zimmer, Eduardo R., Therriault, Joseph, Benedet, Andrea L., Rahmouni, Nesrine, Tissot, Cécile, Stevenson, Jenna, Servaes, Stijn, Triana-Baltzer, Gallen, Kolb, Hartmuth C., Palmqvist, Sebastian, Stomrud, Erik, Rosa-Neto, Pedro, Blennow, Kaj, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501903/
https://www.ncbi.nlm.nih.gov/pubmed/37653254
http://dx.doi.org/10.1038/s43587-023-00471-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501903/
https://www.ncbi.nlm.nih.gov/pubmed/37653254
http://dx.doi.org/10.1038/s43587-023-00471-5

Ejemplares similares